Form D · Pharmaceuticals
Emergo Therapeutics, Inc.
Durham, NC · CIK 0001741198
Offering snapshot reported May 9, 2022 · SEC filing
- Reported sold
- $500K Offering amount: $1.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 26, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 9, 2022 | Initial | $500,000 | No comparison | 2 | SEC filing |
| Oct 13, 2020 | Initial | $3,524,137 | No comparison | 77 | SEC filing |
| Sep 19, 2019 | Amendment | $12,000,000 | No comparison | 110 | SEC filing |
| May 21, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-444966
Source: Form D, filed May 9, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John E. Bailey, Jr. | Director |
| John E. Bailey, Jr. | Director |
| Robert Helmedag | Director |
| Robin Hyde De Ruyscher | Executive |
| Moise Khayrallah | Director, Executive |
| Margaret Powell | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
6208 Fayetteville Road #104
Durham, NC, 27713
Durham, NC, 27713